Specifically, we observed that EVs isolated from AML patients with favorable, intermediate, and adverse prognoses induce metabolic changes that depend on the recipient cells, whether primary AML CD34+ cells or cell lines. This evidence concerns the gene CD34 and acute myeloid leukemia.